<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="mpgn" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">mpgn</book-part-id>
      <title-group>
        <title>Dense Deposit Disease/Membranoproliferative Glomerulonephritis Type II</title>
        <alt-title alt-title-type="alt-title">Synonym: DDD/MPGNII</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cruz Corchado</surname>
            <given-names>Johnny</given-names>
          </name>
          <degrees>PhD candidate</degrees>
          <aff>Molecular Otolaryngology and Renal Research Laboratories <break/>University of Iowa<break/>Iowa City, Iowa</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Richard JH</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Professor of Internal Medicine, Division of Nephrology<break/>Sterba Hearing Research Professor of Otolaryngology <break/>Director, Molecular Otolaryngology and Renal Research Laboratories <break/>University of Iowa <break/>Iowa City, Iowa</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2007-07-20" date-type="created">
          <day>20</day>
          <month>7</month>
          <year>2007</year>
        </date>
        <date iso-8601-date="2011-05-19" date-type="updated">
          <day>19</day>
          <month>5</month>
          <year>2011</year>
        </date>
        <date iso-8601-date="2008-01-02" date-type="revised">
          <day>2</day>
          <month>1</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ddon" document-type="chapter">Deafness-Dystonia-Optic Neuronopathy Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="dent" document-type="chapter">Dent Disease</related-object>
      <abstract id="mpgn.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Dense deposit disease (DDD)/membranoproliferative glomerulonephritis type II (MPGNII) is characterized by onset of hematuria and/or proteinuria, acute nephritic syndrome, or nephrotic syndrome. It most frequently affects children between ages five and 15 years. Spontaneous remissions are uncommon and about 50% of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis. DDD/MPGNII can be associated with acquired partial lipodystrophy (APL). Drusen, whitish-yellow deposits within Bruch's membrane of the retina often develop in the second decade of life; they initially have little impact on vision, but cause vision problems from subretinal neovascular membranes, macular detachment, and central serous retinopathy in about 10% of affected individuals.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The definitive diagnosis of DDD/MPGNII requires electron microscopy and immunofluorescence studies of a renal biopsy. Sequence variants in the genes <italic toggle="yes">CFH</italic>, <italic toggle="yes">CFHR5</italic>, <italic toggle="yes">C3</italic>, and <italic toggle="yes">LMNA</italic> have been implicated in the pathogenesis of DDD/MPGNII, a complex genetic disease that is rarely inherited in a simple Mendelian fashion.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Nonspecific therapies used in numerous chronic glomerular diseases are the mainstay; use of angiotensin-converting enzyme inhibitors, angiotensin II type-1 receptor blockers, and lipid-lowering agents (in particular hydroxymethylglutaryl coenzyme A reductase inhibitors) should be considered; renal allografts have a lower-than-average survival and an almost 100% risk of DDD/MPGNII recurrence.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> In individuals with pathogenic variants in <italic toggle="yes">CFH</italic>, plasma replacement therapy can control complement activation and prevent ESRD.</p>
          <p><italic toggle="yes">Surveillance:</italic> Periodic eye examinations including funduscopic examination.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If two <italic toggle="yes">CFH</italic> pathogenic variants have been identified in an affected individual, sibs can be offered molecular genetic testing to identify those who have the same variants in order to facilitate early diagnosis and management of renal disease.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>DDD/MPGNII is a complex genetic disease that is rarely inherited in a simple Mendelian fashion. Multiple affected persons within a single nuclear family are only reported occasionally; in these instances, parental consanguinity is common. In persons with DDD/MPGNII in whom two pathogenic variants can be identified in <italic toggle="yes">CFH,</italic> inheritance is autosomal recessive. However, in most persons with DDD/MPGNII, two pathogenic variants cannot be identified and risks to family members are not known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="mpgn.Diagnosis">
        <title>Diagnosis</title>
        <sec id="mpgn.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Dense deposit disease (DDD) (also known as membranoproliferative glomerulonephritis type II [MPGNII]) is a complex genetic disease caused by defective regulation of the alternative complement pathway in blood (as opposed to cell surface) that is rarely inherited in a simple Mendelian fashion.</p>
          <p>DDD/MPGNII is typically diagnosed in children age five to 15 years who present with one of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hematuria</p>
            </list-item>
            <list-item>
              <p>Proteinuria</p>
            </list-item>
            <list-item>
              <p>Hematuria and proteinuria</p>
            </list-item>
            <list-item>
              <p>Acute nephritic syndrome</p>
            </list-item>
            <list-item>
              <p>Nephrotic syndrome</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpgn.Testing">
          <title>Testing</title>
          <p><bold>Renal biopsy.</bold> The definitive diagnosis of DDD/MPGNII requires electron microscopy and immunofluorescence studies of a renal biopsy [<xref ref-type="bibr" rid="mpgn.REF.walker.2007.605">Walker et al 2007</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Light microscopy</bold> most commonly demonstrates mild mesangial cell hypercellularity (45% of cases), although membranoproliferative (25%), crescentric (18%), and acute proliferative and exudative (12%) patterns are also seen.</p>
            </list-item>
            <list-item>
              <p><bold>Electron microscopy</bold> should demonstrate dense transformation of the glomerular basement membrane (GBM) that occurs in a segmental, discontinuous, or diffuse pattern in the lamina densa. The precise composition of these altered areas remains unknown.</p>
            </list-item>
            <list-item>
              <p><bold>Immunofluorescence</bold> should be positive for C3, usually in the absence of immunoglobulin deposition.</p>
            </list-item>
          </list>
          <p><bold>Serum C3 nephritic factor (C3NeF).</bold> Most persons with DDD/MPGNII have detectable serum levels of C3NeF. C3NeF is an autoantibody that recognizes neoantigenic epitopes on C3bBb, the C3 convertase of the alternative pathway (AP) of the complement cascade [<xref ref-type="bibr" rid="mpgn.REF.schwertz.2001.166">Schwertz et al 2001</xref>]. C3 convertases cleave C3 into C3b and C3a. In the presence of C3NeF the half-life of C3 convertase is increased, and as a consequence, serum concentrations of C3 are low and serum concentrations of C3 breakdown products such as C3d are elevated.</p>
          <p>Note: (1) Serum concentrations of C3NeF can vary over time and C3NeF may be detected in the serum of persons without renal disease [<xref ref-type="bibr" rid="mpgn.REF.appel.2005.1392">Appel et al 2005</xref>]. (2) C3NeF is also present in up to 50% of individuals with MPGNI and MPGNIII (see <xref ref-type="sec" rid="mpgn.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <p><bold>Factor H autoantibodies</bold> have been reported in the serum of one woman who developed a renal disease consistent with DDD/MPGNII and MPGN type I [<xref ref-type="bibr" rid="mpgn.REF.jokiranta.1999.4590">Jokiranta et al 1999</xref>]. One individual with DDD and a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) had low levels of factor H autoantibodies [<xref ref-type="bibr" rid="mpgn.REF.sethi.2010.977">Sethi et al 2010</xref>].</p>
          <p><bold>Factor B autoantibodies (FBAA)</bold> were identified in a person with DDD without serum C3NeF. FBAA bind to and stabilize C3 convertase, enhancing the consumption of C3. C5 convertase formation from C3 convertase is prevented, thus interfering with activation of the terminal complement cascade (TCC) [<xref ref-type="bibr" rid="mpgn.REF.strobel.2010.1476">Strobel et al 2010</xref>].</p>
          <p><bold>Complement activity.</bold> Hemolytic assays using sheep erythrocytes are used to measure the activity of the alternative pathway (AP) of complement [<xref ref-type="bibr" rid="mpgn.REF.joiner.1983.65">Joiner et al 1983</xref>]. In DDD serum complement-mediated lysis of sheep erythrocytes is observed.</p>
          <sec id="mpgn.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>
              <bold>Genes</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold><italic toggle="yes">CFH</italic></bold> (the gene encoding complement factor H) has been implicated in the pathogenesis of DDD/MPGNII by molecular genetic testing and cell culture studies (see <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">CFHR5</italic></bold> (the gene encoding factor H-related 5) has been implicated in the pathogenesis of DDD/MPGNII by molecular genetic testing; however, no unequivocally pathogenic allelic variants have been reported in <italic toggle="yes">CFHR5</italic> in association with DDD/MPGNII. In 7% of persons with DDD/MPGNII at least one copy of the p.Pro46Ser variant of <italic toggle="yes">CFHR5</italic> is present [<xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</xref>]. (See <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </list-item>
            </list>
            <p><bold>Other possible genes</bold>. Mutation of <italic toggle="yes">C3</italic> and <italic toggle="yes">LMNA</italic> has been reported in one family each. To more completely define the genetics of DDD/MPGNII, molecular genetic testing of multiple complement genes is currently under investigation on a research basis.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold><italic toggle="yes">LMNA</italic>.</bold>
<xref ref-type="bibr" rid="mpgn.REF.owen.2004.c35">Owen et al [2004]</xref> reported one individual with a pathogenic variant in <italic toggle="yes">LMNA</italic> who had both familial partial lipodystrophy type 2 (characterized by fat loss from the face and upper body) and DDD/MPGNII.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">C3</italic>.</bold> A heterozygous pathogenic variant in <italic toggle="yes">C3</italic> (the gene encoding complement component 3) resulting in a &#x00394;DG923 protein (a C3 protein that cannot be cleaved by C3 convertase) was reported in one familial case of DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte et al 2010</xref>].</p>
              </list-item>
            </list>
            <table-wrap id="mpgn.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in DDD/MPGNII</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Inherited DDD/MGNPII Attributed to Pathogenic Variants in This Gene</th>
                    <th id="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">CFH</italic>
                    </td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~10%&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">CFHR5</italic>
                    </td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_mpgn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">None reported&#x000a0;<sup>5</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="mpgn.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="mpgn" object-id="mpgn.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="mpgn.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="mpgn.TF.1.3">
                  <label>3. </label>
                  <p>About 10% of persons with DDD/MPGNII have variants that are likely pathogenic; these are detected by sequence analysis of <italic toggle="yes">CFH</italic> [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>, <xref ref-type="bibr" rid="mpgn.REF.zipfel.2006">Zipfel et al 2006</xref>, <xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2011.1551">Abrera-Abeleda et al 2011</xref>]. 85% of persons with DDD/MPGNII have at least one copy of the His402 variant of <italic toggle="yes">CFH</italic> [<xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</xref>]. (See <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>.)</p>
                </fn>
                <fn id="mpgn.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="mpgn.TF.1.5">
                  <label>5. </label>
                  <p>Pathogenic variants have not yet been reported in <italic toggle="yes">CFHR5</italic>. However, 7% of persons with DDD/MPGNII have at least one copy of the p.Pro46Ser (see <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">CFHR5</italic></bold>) variant of <italic toggle="yes">CFHR5</italic> [<xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="mpgn.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The diagnosis of DDD/MPGNII must be made by renal biopsy, using electron microscopy to demonstrate dense deposits in the GBM.</p>
              <list list-type="bullet">
                <list-item>
                  <p>As a histologically defined disease, DDD/MPGNII lacks unequivocal diagnostic serologic markers of disease activity, although nearly 90% of individuals have C3NeF detectable in serum. (A subgroup of individuals with MPGNI also have C3NeF detectable in serum.)</p>
                </list-item>
                <list-item>
                  <p>In addition, nearly 80% of individuals with DDD/MPGNII have evidence of activation of the alternative pathway of complement as reflected in the serum by low concentrations of C3 and high concentrations of C3 degradation products, including C3d [<xref ref-type="bibr" rid="mpgn.REF.appel.2005.1392">Appel et al 2005</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In persons with a histologic diagnosis of DDD/MPGNII, molecular genetic testing of <italic toggle="yes">CFH</italic> to detect pathogenic variants is appropriate, because identification of such a pathogenic variant helps to direct treatment. Most treatments for DDD/MPGNII are ineffective, but in individuals with pathogenic variants in <italic toggle="yes">CFH</italic>, plasma replacement therapy to replace factor H can control complement activation and prevent end-stage renal disease (ESRD) [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>At this time, the presence of the His402 variant of <italic toggle="yes">CFH</italic> (see <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">CFH</italic></bold>) or of the p.Pro46Ser benign variant in <italic toggle="yes">CFHR5</italic> (see <xref ref-type="sec" rid="mpgn.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">CFHR5</italic></bold>) cannot be used to direct therapy in individuals with DDD/MPGNII. However, molecular genetic testing of <italic toggle="yes">CFH</italic> may be useful (a) in determining whether there is a genetic basis for the diagnosis, and if so, (b) in directing genetic counseling as well as carrier and prenatal testing for at-risk family members.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of two pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="mpgn.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="mpgn.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Renal disease.</bold> Individuals with dense deposit disease/membranoproliferative glomerulonephritis type II (DDD/MPGNII) typically present with one of the five following findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hematuria</p>
            </list-item>
            <list-item>
              <p>Proteinuria</p>
            </list-item>
            <list-item>
              <p>Hematuria and proteinuria</p>
            </list-item>
            <list-item>
              <p>Acute nephritic syndrome</p>
            </list-item>
            <list-item>
              <p>Nephrotic syndrome</p>
            </list-item>
          </list>
          <p>DDD/MPGNII affects females slightly more frequently than males. The DDD Database, a registry that currently contains information on 56 individuals with DDD/MPGNII, reports a 3:2 female:male bias [<xref ref-type="bibr" rid="mpgn.REF.lu.2007.295">Lu et al 2007</xref>].</p>
          <p>Spontaneous remissions of DDD/MPGNII are uncommon [<xref ref-type="bibr" rid="mpgn.REF.habib.1975.204">Habib et al 1975</xref>, <xref ref-type="bibr" rid="mpgn.REF.cameron.1983.175">Cameron et al 1983</xref>, <xref ref-type="bibr" rid="mpgn.REF.marks.2000.322">Marks &#x00026; Rees 2000</xref>]. Although the disease can remain stable for years despite persistent proteinuria, in some individuals rapid fluctuations in proteinuria occur, with episodes of acute renal deterioration in the absence of obvious triggering events.</p>
          <p>About half of affected individuals develop ESRD within ten years of diagnosis [<xref ref-type="bibr" rid="mpgn.REF.di_belgiojoso.1977.250">di Belgiojoso et al 1977</xref>, <xref ref-type="bibr" rid="mpgn.REF.droz.1982.6">Droz et al 1982</xref>, <xref ref-type="bibr" rid="mpgn.REF.swainson.1983.449">Swainson et al 1983</xref>, <xref ref-type="bibr" rid="mpgn.REF.mcenery.1990.s109">McEnery 1990</xref>, <xref ref-type="bibr" rid="mpgn.REF.lu.2007.295">Lu et al 2007</xref>], occasionally with the late comorbidity of impaired visual acuity [<xref ref-type="bibr" rid="mpgn.REF.colville.2003.e2">Colville et al 2003</xref>]. Consistent with these studies, the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) database reports that of the 119 children registered with DDD/MPGNII, 81 have progressed to ESRD [William Harmon, personal communication]. Progression to ESRD develops rapidly, usually within four years of diagnosis, and is the more likely outcome in individuals age ten years or younger than in older persons (p=0.006) [<xref ref-type="bibr" rid="mpgn.REF.smith.2007.2447">Smith et al 2007</xref>]. Girls may have a more aggressive disease course than boys (p=0.16).</p>
          <p><bold>Acquired partial lipodystrophy (APL).</bold> DDD/MPGNII can be associated with APL [<xref ref-type="bibr" rid="mpgn.REF.eisinger.1972.343">Eisinger et al 1972</xref>]. In persons with APL the loss of subcutaneous fat in the upper half of the body usually precedes the onset of kidney disease by several years.</p>
          <p><xref ref-type="bibr" rid="mpgn.REF.misra.2004.18">Misra et al [2004]</xref> reported that approximately 83% of individuals with APL have low serum concentrations of C3 and polyclonal C3NeF, and that about 20% develop DDD/MPGNII approximately eight years after the onset of lipodystrophy. Individuals who develop DDD/MPGNII have an earlier age of onset of lipodystrophy (12.6 &#x000b1; 10.3 yrs vs. 7.7 &#x000b1; 4.4 yrs, respectively; p&#x0003c;0.001) and a higher prevalence of C3 hypocomplementemia (78% vs. 95%, respectively; p=0.02), suggesting that the disease is more virulent in these individuals [<xref ref-type="bibr" rid="mpgn.REF.misra.2004.18">Misra et al 2004</xref>].</p>
          <p><xref ref-type="bibr" rid="mpgn.REF.owen.2004.c35">Owen et al [2004]</xref> described DDD/MPGNII in a person with Dunnigan-Kobberling syndrome, a form of partial lipodystrophy characterized by sparing of the face.</p>
          <p>The association between partial lipodystrophy and DDD/MPGNII appears to be related to the effects of dysregulation of the AP of complement on both kidneys and adipose tissue [<xref ref-type="bibr" rid="mpgn.REF.mathieson.1997.1804">Mathieson &#x00026; Peters 1997</xref>]. The deposition of activated components of complement in adipose tissue results in the destruction of adipocytes in areas in which factor D (fD, adipsin) is high.</p>
          <p><bold>Eye findings.</bold> Individuals with DDD/MPGNII develop drusen, often in the second decade of life. These whitish-yellow deposits lie within Bruch's membrane beneath the retinal pigment epithelium (RPE) of the retina. The distribution of drusen in individuals with DDD/MPGNII is variable [<xref ref-type="bibr" rid="mpgn.REF.duvallyoung.1989.900">Duvall-Young et al 1989</xref>, <xref ref-type="bibr" rid="mpgn.REF.colville.2003.e2">Colville et al 2003</xref>, <xref ref-type="bibr" rid="mpgn.REF.holz.2004.504">Holz et al 2004</xref>] and initially has little impact on visual acuity or visual fields.</p>
          <p>Over time, however, tests of retinal function such as dark adaptation, electroretinography, and electro-oculography can become abnormal, and vision can deteriorate as subretinal neovascular membranes, macular detachment, and central serous retinopathy develop [<xref ref-type="bibr" rid="mpgn.REF.colville.2003.e2">Colville et al 2003</xref>]. The long-term risk of visual problems in individuals with DDD/MPGNII is approximately 10%.</p>
          <p>Drusen are deposits similar in composition and structure to the deposits observed in the kidney [D'souza et al 2009], reflecting similarities between the choriocapillaris-Bruch's membrane-retinal pigment epithelial interface and the capillary tuft-GBM-glomerular epithelial interface.</p>
          <p>No correlation exists between disease severity in the kidney and the eye.</p>
          <p><bold>Autoimmune diseases.</bold> Other autoimmune diseases including diabetes mellitus type 1 and <related-object link-type="booklink" source-id="gene" document-id="celiac" document-type="chapter">celiac disease</related-object> have been observed in families with DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.sacks.1987.175">Sacks et al 1987</xref>, <xref ref-type="bibr" rid="mpgn.REF.ludvigsson.2006.1809">Ludvigsson et al 2006</xref>].</p>
          <p><bold>Pathophysiology.</bold> Fluid-phase dysregulation of the AP of the complement cascade is the triggering pathophysiologic event in DDD/MPGNII, and dysregulation of the C3 convertase alone is necessary and sufficient to result in DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.mart_nezbarricarte.2010.3702">Mart&#x000ed;nez-Barricarte et al 2010</xref>]. However, during disease progression, activation of downstream complement proteins in the solid phase, in particular cleavage of C5 to C5a and C5b, can contribute to tissue injury [<xref ref-type="bibr" rid="mpgn.REF.appel.2005.1392">Appel et al 2005</xref>, <xref ref-type="bibr" rid="mpgn.REF.smith.2007.2447">Smith et al 2007</xref>].</p>
          <p>C3NeF persists in serum throughout the disease course [<xref ref-type="bibr" rid="mpgn.REF.schwertz.2001.166">Schwertz et al 2001</xref>]. Its presence is nearly always associated with evidence of complement activation such as reduction in serum concentration of CH50, decrease in serum concentration of C3, and increase in serum concentration of C3 degradation products such as C3d. However, the relationship between C3NeF, C3, and prognosis is not clear. Some investigators have reported no correlation between C3 serum concentrations and clinical course [<xref ref-type="bibr" rid="mpgn.REF.eisinger.1972.343">Eisinger et al 1972</xref>, <xref ref-type="bibr" rid="mpgn.REF.di_belgiojoso.1977.250">di Belgiojoso et al 1977</xref>, <xref ref-type="bibr" rid="mpgn.REF.davis.1978.184">Davis et al 1978</xref>, <xref ref-type="bibr" rid="mpgn.REF.bennett.1989.469">Bennett et al 1989</xref>], while others found that persistent hypocomplementemia indicates a poor prognosis [<xref ref-type="bibr" rid="mpgn.REF.klein.1983.163">Klein et al 1983</xref>, <xref ref-type="bibr" rid="mpgn.REF.kashtan.1990.1">Kashtan et al 1990</xref>].</p>
          <p>The observed differences may be reconciled by noting that not all C3NeFs are the same, the methods for detecting the presence of C3NeFs vary, and many studies do not report titers. There is good evidence that the triggering epitopes can differ and even change over time.</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="bibr" rid="mpgn.REF.ohi.1992.479">Ohi et al [1992]</xref> provided evidence that triggering epitopes can differ. Their report of six individuals with detectable serum concentration of C3NeF in the absence of hypocomplementemia showed that in these individuals serum C3NeF did not interfere with factor H (fH)-induced inactivation of C3bBb.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="mpgn.REF.spitzer.1996.211">Spitzer &#x00026; Stitzel [1996]</xref> documented that triggering epitopes can change over time. Serum concentration of C3 in three affected persons eventually normalized despite continued C3NeF production. C3NeF isolated from these individuals and added to normal sera mediated consumption of C3, as did the addition of normal factor B (fB) to their sera, consistent with a change in the fB autoantigen in these individuals.</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpgn.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date, no correlations have been reported for the DDD/MPGNII phenotype as a function of genotype. Too few cases have had pathogenic variants of <italic toggle="yes">CFH</italic> to explore phenotype-genotype relationships. It is also possible that pathogenic heterogeneity exists with a final common pathway.</p>
        </sec>
        <sec id="mpgn.Nomenclature">
          <title>Nomenclature</title>
          <p>The designation 'dense deposit disease' (DDD)/MPGNII refers to the electron-dense transformation of the glomerular basement membrane.</p>
          <p>Dense deposit disease is a more accurate name than membranoproliferative glomerulonephritis type II (MPGNII) because (1) only a minority of persons with DDD has a membranoproliferative pattern of histology; and (2) MPGNII implies a relationship to MPGNI and MPGNIII, which is not correct [<xref ref-type="bibr" rid="mpgn.REF.smith.2007.2447">Smith et al 2007</xref>, <xref ref-type="bibr" rid="mpgn.REF.walker.2007.605">Walker et al 2007</xref>, <xref ref-type="bibr" rid="mpgn.REF.pickering.2008.210">Pickering &#x00026; Cook 2008</xref>].</p>
        </sec>
        <sec id="mpgn.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of DDD/MPGNII is estimated to be 2-3:1,000,000 population.</p>
          <p>Epidemiologic data from the past 30 years indicate that the incidence of the membranoproliferative glomerulonephritides, in general, is declining in developed countries [<xref ref-type="bibr" rid="mpgn.REF.jungers.1982.899">Jungers 1982</xref>, <xref ref-type="bibr" rid="mpgn.REF.simon.1984.512">Simon 1984</xref>, <xref ref-type="bibr" rid="mpgn.REF.barbiano_di_belgiojoso.1985.380">Barbiano di Belgiojoso et al 1985</xref>, <xref ref-type="bibr" rid="mpgn.REF.jungers.1985.264">Jungers 1985</xref>, <xref ref-type="bibr" rid="mpgn.REF.gonzalo.1986.161">Gonzalo et al 1986</xref>, <xref ref-type="bibr" rid="mpgn.REF.simon.1987.171">Simon et al 1987</xref>, <xref ref-type="bibr" rid="mpgn.REF.study_group_of_the_spanish_society_of_nephrology.1989.370">Study Group of the Spanish Society of Nephrology 1989</xref>, <xref ref-type="bibr" rid="mpgn.REF.study_group_of_the_spanish_society_of_nephrology.1990.266">Study Group of the Spanish Society of Nephrology 1990</xref>, <xref ref-type="bibr" rid="mpgn.REF.simon.1994.1192">Simon et al 1994</xref>]; most, if not all, of this change can be attributed to a decrease in the incidence of MPGNI. The prevalence of DDD/MPGNII appears to be stable.</p>
        </sec>
      </sec>
      <sec id="mpgn.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">CFH</italic>.</bold> Pathogenic variants in <italic toggle="yes">CFH</italic> cause <related-object link-type="booklink" source-id="gene" document-id="husa" document-type="chapter">atypical hemolytic uremic syndrome</related-object> (aHUS), which is characterized by hemolytic anemia, thrombocytopenia, and renal failure. The thrombotic microangiopathy of aHUS damages endothelial cells and causes detachment of the basement membrane.</p>
        <p>Although most typical HUS is caused by Gram-negative bacteria that produce shiga toxin (<italic toggle="yes">Shigella dysenteriae</italic> serotype 1; <italic toggle="yes">Escherichia coli</italic> serotypes O-157, O-111, O-26), atypical HUS is caused by pathogenic loss-of-function or gain-of-function variants in several genes encoding regulators (<italic toggle="yes">CFH</italic>, <italic toggle="yes">CFHR1</italic>, <italic toggle="yes">CFI</italic>, and <italic toggle="yes">MCP</italic>) or activators (<italic toggle="yes">C3</italic>, <italic toggle="yes">CFB</italic>), respectively, of the alternative pathway (AP) of complement [<xref ref-type="bibr" rid="mpgn.REF.goodship.2006">Goodship et al 2006</xref>, <xref ref-type="bibr" rid="mpgn.REF.zipfel.2006">Zipfel et al 2006</xref>]. The result of these pathogenic variants is impaired protection of host surfaces against complement activation [<xref ref-type="bibr" rid="mpgn.REF.saunders.2007.222">Saunders et al 2007</xref>].</p>
        <p>The most common mutated gene is <italic toggle="yes">CFH</italic>, which encodes CFH, an important regulator of the AP. <italic toggle="yes">CFH</italic> pathogenic variants are reported in 20%-30% of individuals with aHUS. More than 40% of the identified pathogenic variants are located in a portion of <italic toggle="yes">CFH</italic> that encodes SCRs 19 and 20 of the factor H protein [<xref ref-type="bibr" rid="mpgn.REF.saunders.2007.222">Saunders et al 2007</xref>]. These pathogenic variants, which affect only one allele and lead to haploinsufficiency, include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Variants that lead to premature stop codons;</p>
          </list-item>
          <list-item>
            <p>Variants that affect framework cysteine residues and prevent disulfide bond formation and the adoption of the appropriate conformational structure;</p>
          </list-item>
          <list-item>
            <p>Non-framework variants that affect protein expression, result in a defective secreted protein, or severely impair capability to bind to endothelial cell surfaces.</p>
          </list-item>
        </list>
        <p>The benign allelic variant <xref ref-type="table" rid="mpgn.T.selected_cfh_allelic_variants">c.1204T&#x0003e;C</xref> (p.Tyr402His) of factor H affects the risk of age-related macular degeneration (AMD): the c.1204C (His402) variant significantly increases the risk of (AMD) [<xref ref-type="bibr" rid="mpgn.REF.haines.2005.419">Haines et al 2005</xref>].</p>
        <p><bold><italic toggle="yes">CFHR5</italic>.</bold> A complex rearrangement of <italic toggle="yes">CFHR5</italic> producing a mutated protein in which the first two short consensus repeats (SCRs) are duplicated (<italic toggle="yes">CFHR5<sup>12123&#x000a0;9</sup></italic>) was found in 26 individuals from Cyprus with 'CFHR5 nephropathy', a C3 glomerulopathy similar to DDD/MPGNII that is common in Cyprus. (See also <xref ref-type="sec" rid="mpgn.Differential_Diagnosis">Differential Diagnosis</xref>.)</p>
      </sec>
      <sec id="mpgn.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The membranoproliferative glomerulonephritides are diseases of diverse and often obscure etiology and pathogenetic mechanisms; they account for approximately 4% and 7% of primary renal causes of nephrotic syndrome in children and adults, respectively [<xref ref-type="bibr" rid="mpgn.REF.orth.1998.1202">Orth &#x00026; Ritz 1998</xref>].</p>
        <p>Based on immunopathology and ultrastructure analysis of the kidney, and of the glomerulus in particular, three subtypes of membranoproliferative glomerulonephritides are recognized.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Membranoproliferative glomerulonephritis types I and III (MPGNI, MPGNIII)</bold> are variants of immune complex-mediated disease. MPGNI is characterized by the presence of subendothelial deposits and MPGNIII by the concomitant presence of subendothelial and subepithelial deposits, suggesting that MPGNIII is possibly a morphologic variant of MPGNI, given their clinical, immunologic, and immunohistologic similarities [<xref ref-type="bibr" rid="mpgn.REF.ferrario.2004.483">Ferrario &#x00026; Rastaldi 2004</xref>]. Of note, however, treatment outcomes following alternate-day prednisone therapy are better for those with MPGNI than for those with MPGNIII [<xref ref-type="bibr" rid="mpgn.REF.braun.1999.1022">Braun et al 1999</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>DDD/MPGNII</bold> has no known association with immune complexes. In DDD/MPGNII, pathognomonic dense intramembranous deposits cause capillary wall thickening. Although the list of diseases associated with an MPGN-like pattern and capillary wall thickening is constantly growing, the differences in histology and immunology are sufficient to consider DDD/MPGNII an entity separate and discrete from either MPGNI or III. DDD/MPGNII accounts for fewer than 20% of children with MPGN and fewer than 1% of adults with MPGN [<xref ref-type="bibr" rid="mpgn.REF.habib.1975.204">Habib et al 1975</xref>].</p>
          </list-item>
        </list>
        <p>Other types of glomerulonephritis with deposition of C3 are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Glomerulonephritis C3</bold> (GN-C3), characterized by the presence of isolated mesangial C3 deposits. The main difference between DDD/MPGNII and GN-C3 is the absence of intramembranous deposits within the GBM in the latter [<xref ref-type="bibr" rid="mpgn.REF.servais.2007.193">Servais et al 2007</xref>]. Based on renal biopsy findings, GN-C3 can be divided in two types: GN-C3 with MPGN (mesangial proliferation and subendothelial C3 deposits); and GN-C3 without MPGN (no mesangial proliferation and subendothelial C3 deposits) [<xref ref-type="bibr" rid="mpgn.REF.servais.2007.193">Servais et al 2007</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>CFHR5 nephropathy</bold>, a nephropathy found in Cypriots characterized by isolated microscopic hematuria that can rapidly progress to renal failure and macroscopic hematuria following an upper respiratory tract infection. Inheritance is autosomal dominant. The cause is partial duplication of <italic toggle="yes">CFHR5</italic> (<italic toggle="yes">CFHR5<sup>12123&#x000a0;9</sup></italic>) that generates a hybrid protein with two additional short consensus repeats (SCRs). The hybrid CFHR5 protein binds weakly to complement deposited in the glomerulus [<xref ref-type="bibr" rid="mpgn.REF.gale.2010.794">Gale et al 2010</xref>]. (See <xref ref-type="sec" rid="mpgn.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</xref>.)</p>
          </list-item>
        </list>
        <p>Other diseases to consider in the differential diagnosis of the renal manifestations of DDD/MPGNII:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Juvenile acute non-proliferative glomerulonephritis (JANG),</bold> a disease exclusively of the young (no affected individual exceeded age 12 years in the report by <xref ref-type="bibr" rid="mpgn.REF.west.2000.786">West et al [2000]</xref>). JANG is characterized by rapid crescent formation but no mesangial cell proliferation. Large subepithelial deposits that contain C3 and C5 but no IgG develop on the paramesangial portion of the GBM. JANG can be distinguished from DDD/MPGNII on clinical grounds as the latter is typically associated with C3NeF-induced hypocomplementemia, often with nephrotic syndrome and hypertension, while in JANG, serum concentrations of C3 remain at the lower limits of normal [<xref ref-type="bibr" rid="mpgn.REF.west.2000.786">West et al 2000</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Familial lecithin-cholesterol acyltransferase (LCAT) deficiency,</bold> an autosomal recessive disorder characterized by corneal opacities, normochromic normocytic anemia, and renal dysfunction that can progress to ESRD. High serum concentrations of an abnormal lipoprotein (lipoprotein X) cause glomerular capillary endothelial damage and glomerular deposition of membrane-like, cross-striated structures and vacuole structures. One individual with LCAT deficiency showed glomerular histologic lesions and an immunofluorescent glomerular pattern typical of DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.sessa.2001.268">Sessa et al 2001</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Partial lipodystrophy (PLD)</bold> can be associated with DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.eisinger.1972.343">Eisinger et al 1972</xref>]. In persons with PLD, the loss of subcutaneous fat in the upper half of the body usually precedes the onset of kidney disease by several years. The relationship between the two diseases reflects the effects of dysregulation of the AP of the complement cascade on kidney and adipose tissue [<xref ref-type="bibr" rid="mpgn.REF.mathieson.1997.1804">Mathieson &#x00026; Peters 1997</xref>]. The deposition of activated components of complement in adipose tissue results in the destruction of adipocytes in areas high in content of factor D (fD, adipsin).</p>
          </list-item>
        </list>
        <p>The retinal abnormalities of DDD/MPGNII are similar to those seen in the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Age-related macular degeneration (AMD),</bold> the most common cause of visual loss in the US in persons older than age 50 years. AMD is characterized by the development of whitish-yellow deposits within Bruch's membrane beneath the RPE. In DDD/MPGNII, drusen develop at an early age and are often detectable in the second decade of life. Both AMD and DDD/MPGNII are associated with common 'at-risk' alleles of <italic toggle="yes">CFH</italic> [<xref ref-type="bibr" rid="mpgn.REF.hageman.2005.7227">Hageman et al 2005</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Malattia leventinese</bold> and <bold>Doyne honeycomb retinal dystrophy,</bold> two autosomal dominant disorders in which drusen accumulate beneath the RPE. The two disorders are phenotypically similar to AMD [<xref ref-type="bibr" rid="mpgn.REF.stone.1999.199">Stone et al 1999</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="mpgn.Management">
        <title>Management</title>
        <sec id="mpgn.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>After the diagnosis of dense deposit disease/membranoproliferative glomerulonephritis type II (DDD/MPGNII) has been made, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Evaluate the complement system by measuring serum concentration of CH50, APH50, C3, C3d, C4, factor H and sMAC. (For a list of laboratories providing these tests, contact Richard Smith. See <xref ref-type="sec" rid="mpgn.Author_Notes">Author Notes</xref>.)</p>
              <list list-type="bullet">
                <list-item>
                  <p>Complement protein measures in DDD/MPGNII are distinctive, with most patients having only low serum concentrations of C3, while serum concentrations of properdin, C5, and other terminal proteins are within the normal range.</p>
                </list-item>
                <list-item>
                  <p>Factor H serum concentrations can be low, as has been reported with pathogenic missense variants in the <italic toggle="yes">CFH</italic> coding sequence that block protein secretion from the endoplasmic reticulum [<xref ref-type="bibr" rid="mpgn.REF.ault.1997.25168">Ault et al 1997</xref>, <xref ref-type="bibr" rid="mpgn.REF.dragondurey.2004.787">Dragon-Durey et al 2004</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Measure autoantibodies including C3NeF, factor H autoantibodies (FHAA) and factor B autoantibodies (FBAA).</p>
            </list-item>
            <list-item>
              <p>Screen <italic toggle="yes">CFH</italic> for pathogenic variants using bidirectional sequencing.</p>
            </list-item>
            <list-item>
              <p>Establish the extent of renal disease by measuring serum creatinine concentration, and monitor creatinine clearance, proteinuria and hematuria.</p>
            </list-item>
            <list-item>
              <p>Obtain a baseline ophthalmologic examination [<xref ref-type="bibr" rid="mpgn.REF.mcavoy.2004.331">McAvoy et al 2004</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpgn.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Nonspecific therapies</bold> have been shown to be effective in numerous chronic glomerular diseases and should be initiated. The judicious use of these agents, along with optimal blood pressure control, may be of benefit in individuals with DDD/MPGNII.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor blockers</bold> decrease proteinuria in many glomerular diseases and slow the progression to renal failure [<xref ref-type="bibr" rid="mpgn.REF.ruggenenti.1999.359">Ruggenenti et al 1999</xref>, <xref ref-type="bibr" rid="mpgn.REF.brenner.2001.861">Brenner et al 2001</xref>]. A retrospective study found that the combination of angiotensin blockers and immunosuppressants (steroids) is more effective than each therapy alone in preventing the development of renal failure [<xref ref-type="bibr" rid="mpgn.REF.nasr.2009.22">Nasr et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Lipid-lowering agents,</bold> and in particular hydroxymethylglutaryl coenzyme A reductase inhibitors, may delay progression of renal disease as well as correct endothelial cell dysfunction and alter long-term atherosclerotic risks in the presence of hyperlipidemia [<xref ref-type="bibr" rid="mpgn.REF.nickolas.2003.406">Nickolas et al 2003</xref>, <xref ref-type="bibr" rid="mpgn.REF.maisch.2004.342">Maisch &#x00026; Pezzillo 2004</xref>]. These agents are not widely used in children.</p>
            </list-item>
          </list>
          <p><bold>Renal allografts.</bold> Fewer than 200 individuals with DDD/MPGNII have undergone transplantation [<xref ref-type="bibr" rid="mpgn.REF.braun.2005.2225">Braun et al 2005</xref>]. Five-year allograft survival approximates 50%, which is significantly worse than for the NAPRTCS database as a whole (p=0.001). Living-related donor grafts fare better than deceased donor grafts (p&#x0003c;0.005). Allograft survival appears to be age-dependent in DDD; the survival of pediatric DDD transplant recipients is significantly worse than the rest of the pediatric transplant population [<xref ref-type="bibr" rid="mpgn.REF.angelo.2011.291">Angelo et al 2011</xref>].</p>
          <p>DDD/MPGNII recurs in nearly all grafts and is the predominant cause of graft failure in 15%-50% of transplant recipients [<xref ref-type="bibr" rid="mpgn.REF.appel.2005.1392">Appel et al 2005</xref>, <xref ref-type="bibr" rid="mpgn.REF.angelo.2011.291">Angelo et al 2011</xref>]. There are little data to suggest that any therapeutic interventions have an effect on reversing this course, although isolated reports have described the use of plasmapheresis, which appears to be of equivocal benefit [<xref ref-type="bibr" rid="mpgn.REF.fr_meauxbacchi.1994.811">Fr&#x000e9;meaux-Bacchi et al 1994</xref>, <xref ref-type="bibr" rid="mpgn.REF.kurtz.2002.135">Kurtz &#x00026; Schlueter 2002</xref>].</p>
        </sec>
        <sec id="mpgn.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Although most treatment for DDD/MPGNII is ineffective, plasma replacement therapy in patients with pathogenic variants in <italic toggle="yes">CFH</italic> can control complement activation and prevent ESRD [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>].</p>
        </sec>
        <sec id="mpgn.Surveillance">
          <title>Surveillance</title>
          <p>Periodic funduscopic assessment is appropriate [<xref ref-type="bibr" rid="mpgn.REF.mcavoy.2004.331">McAvoy et al 2004</xref>].</p>
        </sec>
        <sec id="mpgn.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If pathogenic variants in <italic toggle="yes">CFH</italic> have been identified in an affected individual, sibs can be offered molecular genetic testing to identify those who have the same variant(s) in order to facilitate early diagnosis and management of renal disease. Penetrance rates, however, are not known.</p>
          <p>See <xref ref-type="sec" rid="mpgn.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="mpgn.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>A clinical study using eculizumab in persons with DDD/MPGN2 or C3 glomerulonephritis who are age 18 years and older is ongoing but is not recruiting new patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01221181?term=mpgn&#x00026;rank=2">ClinicalTrials.gov</ext-link>).</p>
          <p>A clinical study using sulodexide in persons with DDD/MPGNII who are under age 21 years was put on inactive status as no beneficial effect was noted in patients with diabetic nephropathy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00583427?term=mpgn&#x00026;rank=3">ClinicalTrials.gov</ext-link>).</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="mpgn.Other">
          <title>Other</title>
          <p>The impact of genotype on graft survival has not yet been explored.</p>
          <p>Experience with intravenous immunoglobulin (IVIg) and B cell suppression is limited.</p>
          <p>The following treatment modalities are of unproven value:</p>
          <p><bold>Plasmapheresis</bold> to remove or suppress serum C3NeF activity:</p>
          <list list-type="bullet">
            <list-item>
              <p>In one study, one of three adults with DDD/MPGNII experienced improvement in serum creatinine during plasmapheresis [<xref ref-type="bibr" rid="mpgn.REF.mcginley.1985.385">McGinley et al 1985</xref>].</p>
            </list-item>
            <list-item>
              <p>Another study reported success using plasmapheresis to treat a five-year-old boy with recurrent DDD/MPGNII after transplantation. Twelve phereses were performed over 24 days, and the child continued to have improved renal function one year later [<xref ref-type="bibr" rid="mpgn.REF.oberkircher.1988.418">Oberkircher et al 1988</xref>].</p>
            </list-item>
            <list-item>
              <p>In another report, a 15-year-old girl with rapidly progressive recurrent DDD/MPGNII in her allograft underwent 73 phereses over 63 weeks, stabilizing her creatinine and improving her creatinine clearance. Serial biopsies during this time demonstrated persistent DDD/MPGNII without development of tubular atrophy. During the course of therapy, serum C3NeF activity decreased and C3NeF activity was detected in the removed plasma. Because of the morbidity associated with repeated phereses, treatment was discontinued and graft failure ensued [<xref ref-type="bibr" rid="mpgn.REF.kurtz.2002.135">Kurtz &#x00026; Schlueter 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>In another report, two patients with a pathogenic variant in <italic toggle="yes">CFH</italic> were successfully treated with fresh frozen plasma [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>].</p>
            </list-item>
          </list>
          <p><bold>Prednisone.</bold> Although long-term controlled studies of prednisone therapy have suggested a possible benefit as measured by a decrease in proteinuria and prolonged renal survival in children with MPGN type I-III [<xref ref-type="bibr" rid="mpgn.REF.west.1986.1077">West 1986</xref>, <xref ref-type="bibr" rid="mpgn.REF.mcenery.1990.s109">McEnery 1990</xref>], a randomized placebo-controlled study found that while evidence showed an overall benefit in individuals with MPGNI, II, and III combined, children with DDD/MPGNII had no better response to prednisone than to lactose, with treatment failure defined as a creatinine greater than 350 mmol/L (4 mg/dL) in 55.6% (5/9) and 60% (3/5) of individuals, respectively [<xref ref-type="bibr" rid="mpgn.REF.tarshish.1992.123">Tarshish et al 1992</xref>].</p>
          <p>Available data on steroid therapy in adults with DDD/MPGNII suggest a similar lack of efficacy [<xref ref-type="bibr" rid="mpgn.REF.donadio.1989.445">Donadio &#x00026; Offord 1989</xref>].</p>
          <p>Note: The use of steroid therapy is extremely effective in JANG, which can be confused with DDD/MPGNII. The two diseases can be distinguished clinically, as DDD/MPGNII is typically associated with C3NeF-induced hypocomplementemia, often with nephrotic syndrome and hypertension, while in JANG, C3 levels remain at the lower limit of normal [<xref ref-type="bibr" rid="mpgn.REF.west.2000.786">West et al 2000</xref>].</p>
          <p><bold>Calcineurin inhibitors.</bold> When evaluated in small numbers of individuals, the calcineurin inhibitors do not improve renal survival in DDD/MPGNII. Furthermore, in vitro studies with two calcineurin inhibitors, cyclosporin and tacrolimus, have shown that at therapeutic concentrations neither drug suppresses C3 transcription [<xref ref-type="bibr" rid="mpgn.REF.sacks.2003.404">Sacks &#x00026; Zhou 2003</xref>]. Given the evidence that uncontrolled activation of the AP of the complement cascade is the basis of MPGNII/DDD, it is not surprising that these drugs are clinically ineffective immunomodulatory treatment modalities.</p>
          <p><bold>Combined therapy with immunosuppression (IS) and renin aingotensin system (RAS) blockade.</bold> In a retrospective study, the combined use of IS (steroids) and RAS blockade (angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blocker) was protective against developing end-stage renal disease (ESRD). The IS/RAS blockade therapy was superior to the use of either agent alone. These findings need to be confirmed by a prospective control study [<xref ref-type="bibr" rid="mpgn.REF.nasr.2009.22">Nasr et al 2009</xref>].</p>
          <p><bold>Bevacizumab.</bold> In one study, a 29-year-old woman with DDD/MPGNII and subretinal neovascular membranes was treated with monthly intravitreal injections of bevacizumab. An improvement in vision was noted; renal function remained unaltered [<xref ref-type="bibr" rid="mpgn.REF.farah.2009.416">Farah et al 2009</xref>].</p>
        </sec>
      </sec>
      <sec id="mpgn.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="mpgn.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Dense deposit disease/membranoproliferative glomerulonephritis type II (DDD/MPGNII) is a complex genetic disorder that is rarely inherited in a simple Mendelian fashion. In most persons with DDD/MPGNII, the inheritance is complex and incompletely understood. For these reasons, recurrence risk to family members is not known but likely very low.</p>
          <list list-type="bullet">
            <list-item>
              <p>Multiple affected persons within a single nuclear family are only reported occasionally; in these instances, parental consanguinity is common [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>In persons with DDD/MPGNII in whom two pathogenic variants can be identified in <italic toggle="yes">CFH</italic> inheritance is autosomal recessive.</p>
            </list-item>
          </list>
        </sec>
        <sec id="mpgn.Risk_to_Family_Members__Autosomal_R">
          <title>Risk to Family Members &#x02014; Autosomal Recessive DDD/MPGNII</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutated allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with DDD/MPGNII are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">CFH</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="mpgn.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if two <italic toggle="yes">CFH</italic> pathogenic variants have been identified in an affected family member.</p>
        </sec>
        <sec id="mpgn.Risk_to_Family_Members__Other_Etiol">
          <title>Risk to Family Members &#x02014; Other Etiologies</title>
          <p><bold>Parents, sibs, and offspring of a proband.</bold> The risk to the family members of a proband who does not have <italic toggle="yes">CFH</italic> pathogenic variants, the <italic toggle="yes">CFHR5</italic> common variant, or a family history consistent with autosomal recessive or dominant inheritance is low.</p>
        </sec>
        <sec id="mpgn.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="mpgn.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>DDD/MPGNII can be seen in families in which other members have other complex autoimmune diseases, such as diabetes mellitus type 1 and <related-object link-type="booklink" source-id="gene" document-id="celiac" document-type="chapter">celiac disease</related-object> [<xref ref-type="bibr" rid="mpgn.REF.smith.2007.2447">Smith et al 2007</xref>].</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="mpgn.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>If two pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
        </sec>
      </sec>
      <sec id="mpgn.Resources">
        <title>Resources</title>
      </sec>
      <sec id="mpgn.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">CFH</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">CFH</italic> comprises 23 exons that encode complement factor H, a protein of 1234 amino acids. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mpgn" object-id="mpgn.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Of the several alleles of <italic toggle="yes">CFH</italic>, the one that encodes a His at residue 402 is of particular interest because of the association of this amino acid substitution with DDD/MPGNII and AMD [<xref ref-type="bibr" rid="mpgn.REF.hageman.2005.7227">Hageman et al 2005</xref>, <xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</xref>]. The c.1204T&#x0003e;C (p.Tyr402His) benign allelic variant is in SCR(short consensus repeat)7, one of at least three glycosaminoglycan (GAG) recognition sites in factor H. SCR7 participates in binding to C-reactive protein (CRP) and to a number of pathogens that sequester factor H as protection from complement-mediated destruction. Structural studies have shown that p.Tyr402His lies toward the center of SCR7, away from its boundaries with SCR8 and SCR9. The 3D structures of both the His402 and Tyr402 protein variants are otherwise identical [<xref ref-type="bibr" rid="mpgn.REF.herbert.2007.18960">Herbert et al 2007</xref>]. In spite of this similarity, binding studies indicate that the p.Tyr402His change alters the specific types of GAGs that are recognized by SCR7. For example, binding to both human umbilical vein endothelial cells and to C-reactive protein is reduced for the His402 protein variant as compared to the Tyr402 protein variant [<xref ref-type="bibr" rid="mpgn.REF.laine.2007.3831">Laine et al 2007</xref>, <xref ref-type="bibr" rid="mpgn.REF.skerka.2007.3398">Skerka et al 2007</xref>].</p>
        <p><bold>Pathogenic allelic variants.</bold>
<italic toggle="yes">CFH</italic> has been implicated in DDD/MPGNII by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A report of two sisters with DDD/MPGNII who were homozygous for the <xref ref-type="table" rid="mpgn.T.selected_cfh_allelic_variants">c.670_672delAAG</xref> (p.Lys224del) pathogenic variant in <italic toggle="yes">CFH</italic> [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>, <xref ref-type="bibr" rid="mpgn.REF.zipfel.2006">Zipfel et al 2006</xref>]. As a result of this amino acid deletion in factor H, the N-terminal activities of the mutated protein (C3b binding and complement regulation) were defective, indicating that dysfunctional factor H protein is associated with the development of DDD/MPGNII [<xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al 2006</xref>].</p>
          </list-item>
          <list-item>
            <p>Studies of skin fibroblasts from a factor H-deficient child with chronic hypocomplementemic renal disease. Normal amounts of 4.3- and 1.8-kb messages were observed, but secretion of the 155-kd protein was blocked; the 45-kd protein was secreted with normal kinetics. Consistent with this finding, the affected individual's plasma lacked the 155-kd factor H protein but contained the smaller factor H-like 1 protein. The 155-kd factor H protein was retained in the endoplasmic reticulum and was not degraded even after 12 hours. Pathogenic variant screening of CFH revealed a <xref ref-type="table" rid="mpgn.T.selected_cfh_allelic_variants">c.1607G&#x0003e;A</xref> substitution on one allele and a 2949G&#x0003e;A substitution on the other, predicting a p.Cys536Arg change in short consensus repeat SCR9 and a p.Cys959Tyr change in SCR16, respectively. Both pathogenic variants affect conserved cysteine residues characteristic of the SCR modules of factor H and therefore predict profound changes in the higher-order structure of the 155-kd protein [<xref ref-type="bibr" rid="mpgn.REF.ault.1997.25168">Ault et al 1997</xref>].</p>
          </list-item>
          <list-item>
            <p>Pathogenic variant screening results in two brothers with MPGN who were homozygous for a <xref ref-type="table" rid="mpgn.T.selected_cfh_allelic_variants">p.Arg127Leu</xref> amino acid change in <italic toggle="yes">CFH</italic> [<xref ref-type="bibr" rid="mpgn.REF.dragondurey.2004.787">Dragon-Durey et al 2004</xref>]</p>
          </list-item>
        </list>
        <table-wrap id="mpgn.T.selected_cfh_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">CFH</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">SCR (Domain) of the Factor H Protein&#x000a0;<sup>2</sup></th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type of Variant</th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                <th id="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1204T&#x0003e;C</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His402Tyr&#x000a0;<sup>3</sup></td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">SCR7</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_7" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000186.3">NM_000186.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000177.2">NP_000177.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.380G&#x0003e;T</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg127Leu&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">SCR2</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Missense, homozygous</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="mpgn.REF.dragondurey.2004.787">Dragon-Durey et al [2004]</xref>&#x000a0;<sup>5</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.670_672delAAG</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys224del&#x000a0;<sup>4</sup><break/>(&#x00394;Lys224)</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">SCR4</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Deletion, homozygous</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">
                  <xref ref-type="bibr" rid="mpgn.REF.licht.2006.42">Licht et al [2006]</xref>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1606T&#x0003e;C<break/>(1679T&#x0003e;C)</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys536Arg&#x000a0;<sup>4</sup><break/>(Cys518Arg)&#x000a0;<sup>6</sup></td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">SCR9</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Missense</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_6" rowspan="2" valign="middle" align="left" colspan="1">
                  <xref ref-type="bibr" rid="mpgn.REF.ault.1997.25168">Ault et al [1997]</xref>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2876G&#x0003e;A<break/>(2949G&#x0003e;A)</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys959Tyr&#x000a0;<sup>3</sup><break/>(Cys991Tyr)</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">SCR16</td>
                <td headers="hd_h_mpgn.T.selected_cfh_allelic_variants_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Missense</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="mpgn.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="mpgn.TF.2.2">
              <label>2. </label>
              <p>SCR = short consensus repeat</p>
            </fn>
            <fn id="mpgn.TF.2.3">
              <label>3. </label>
              <p>Although considered a benign allelic variant, the functional properties differ between proteins with the His402 and the Tyr402 amino acid residues.</p>
            </fn>
            <fn id="mpgn.TF.2.4">
              <label>4. </label>
              <p>Signal peptide included</p>
            </fn>
            <fn id="mpgn.TF.2.5">
              <label>5. </label>
              <p>This paper includes additional <italic toggle="yes">CFH</italic> pathogenic variants associated with other types of MPGN.</p>
            </fn>
            <fn id="mpgn.TF.2.6">
              <label>6. </label>
              <p>Signal peptide not included</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The normal gene product encoded by <italic toggle="yes">CFH</italic> is complement factor H, a plasma glycoprotein (155 kd) present in blood at concentrations ranging from approximately 500 to 800 &#x000b5;g/mL. It is organized in repetitive elements termed short consensus repeats (SCRs) and controls the alternative pathway (AP) of complement activation, both in fluid phase and on cellular surfaces by binding to three sites on C3b destabilizing C3bBb. In the fluid phase, this interaction results in dissociation of C3bBb into inactive fBb (ifBb) and C3bfH, which is irreversibly inactivated into iC3b by factor I [<xref ref-type="bibr" rid="mpgn.REF.pangburn.1986.723">Pangburn &#x00026; Muller-Eberhard 1986</xref>]. On cellular surfaces, the inactivation of bound C3b is dependent on the chemical composition of the surface to which C3b is bound [<xref ref-type="bibr" rid="mpgn.REF.rodr_guez_de_c_rdoba.2004.355">Rodr&#x000ed;guez de C&#x000f3;rdoba et al 2004</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Homozygosity for the c.380G&#x0003e;T pathogenic missense variant is associated with absence of factor H in the serum, suggesting that this variant results in sequestration of the protein in the endoplasmic reticulum. In contrast, the factor H with the pathogenic variant p.Lys224del is present in the serum at normal concentrations but is non-functional [<xref ref-type="bibr" rid="mpgn.REF.zipfel.2006">Zipfel et al 2006</xref>].</p>
        <p>
          <bold>
            <italic toggle="yes">CFHR5</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">CFHR5</italic> comprises ten exons that encode complement factor H related 5 (CFHR5), a protein of 551 amino acids organized into nine SCRs. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mpgn" object-id="mpgn.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Several allelic variants have been reported in the normal population, some of which are over-represented in persons with DDD/MPGNII and <related-object link-type="booklink" source-id="gene" document-id="husa" document-type="chapter">atypical hemolytic uremic syndrome</related-object> [<xref ref-type="bibr" rid="mpgn.REF.abreraabeleda.2006.582">Abrera-Abeleda et al 2006</xref>, <xref ref-type="bibr" rid="mpgn.REF.monteferrante.2007.1704">Monteferrante et al 2007</xref>]. One such example is the p.Pro46Ser variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_030787.2">NM_030787.2</ext-link>:c.136C&#x0003e;T).</p>
        <p><bold>Pathogenic allelic variants.</bold> No unequivocally pathogenic allelic variants have been reported in <italic toggle="yes">CFHR5</italic> in association with DDD/MPGNII.</p>
        <p><bold>Normal gene product.</bold> The normal gene product encoded by <italic toggle="yes">CFHR5</italic> is complement factor H-related protein 5 (CFHR5), a plasma protein organized like CFH in repetitive SCRs. CFHR5 has nine SCRs and is the only CFHR protein that is like CFH in its ability to inhibit C3 convertase in the fluid phase. CFHR5 also possesses complement factor I-dependent cofactor activity that leads to inactivation of C3b [<xref ref-type="bibr" rid="mpgn.REF.mcrae.2001.6747">McRae et al 2001</xref>, <xref ref-type="bibr" rid="mpgn.REF.rodr_guez_de_c_rdoba.2004.355">Rodr&#x000ed;guez de C&#x000f3;rdoba et al 2004</xref>, <xref ref-type="bibr" rid="mpgn.REF.mcrae.2005.6250">McRae et al 2005</xref>]. In 92 renal biopsies from patients with different glomerular diseases, CFHR5 was present in all complement-containing glomerular immune deposits [<xref ref-type="bibr" rid="mpgn.REF.murphy.2002.24">Murphy et al 2002</xref>], suggesting that CFHR5 plays an important role in protecting the glomerulus from complement activation. The role of CFHR5 in the physiopathology of DDD/MPGNII remains to be elucidated.</p>
        <p><bold>Abnormal gene product.</bold> No abnormal gene product of <italic toggle="yes">CFHR5</italic> has been reported in association with DDD/MPGNII.</p>
      </sec>
      <sec id="mpgn.References">
        <title>References</title>
        <sec id="mpgn.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="mpgn.Literature_Cited.reflist0">
            <ref id="mpgn.REF.abreraabeleda.2011.1551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abrera-Abeleda</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frees</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJH</given-names>
                  </name>
                </person-group>
                <article-title>Allele variants of complement genes associated with dense deposit disease.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2011</year>
                <volume>22</volume>
                <fpage>1551</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21784901</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.abreraabeleda.2006.582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abrera-Abeleda</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McRae</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvestri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skerka</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f3;zsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).</article-title>
                <source>J Med Genet.</source>
                <volume>43</volume>
                <fpage>582</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16299065</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.angelo.2011.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Angelo</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis.</article-title>
                <source>Am J Kidney Dis.</source>
                <volume>57</volume>
                <fpage>291</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21215503</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.appel.2005.1392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Appel</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennette</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashgarian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirschfink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambris</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanning</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>HU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salant</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smoyer</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tully</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tully</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welsh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wurzner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>16</volume>
                <fpage>1392</fpage>
                <lpage>403</lpage>
                <pub-id pub-id-type="pmid">15800116</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.ault.1997.25168">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ault</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>BZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fowler</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colten</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism.</article-title>
                <source>J Biol Chem</source>
                <volume>272</volume>
                <fpage>25168</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">9312129</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.barbiano_di_belgiojoso.1985.380">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barbiano di Belgiojoso</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baroni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagliari</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavagni</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porri</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banfi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colasanti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Confalonieri</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Is membranoproliferative glomerulonephritis really decreasing? A multicentre study of 1,548 cases of primary glomerulonephritis.</article-title>
                <source>Nephron</source>
                <volume>40</volume>
                <fpage>380</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">4010856</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.bennett.1989.469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassett</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fairley</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Apice</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kincaid-Smith</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>13</volume>
                <fpage>469</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">2658560</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.braun.2005.2225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stablein</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamiwka</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartosh</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strife</surname>
                    <given-names>CF</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>16</volume>
                <fpage>2225</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">15888559</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.braun.1999.1022">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strife</surname>
                    <given-names>CF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>34</volume>
                <fpage>1022</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">10585311</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.brenner.2001.861">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Zeeuw</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keane</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitch</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parving</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remuzzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snapinn</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahinfar</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.</article-title>
                <source>N Engl J Med</source>
                <volume>345</volume>
                <fpage>861</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11565518</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.cameron.1983.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heaton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogg</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chantler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haycock</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hicks</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.</article-title>
                <source>Am J Med</source>
                <volume>74</volume>
                <fpage>175</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">6337487</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.colville.2003.e2">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Colville</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guymer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savige</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease").</article-title>
                <source>Am J Kidney Dis</source>
                <volume>42</volume>
                <fpage>E2</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12900843</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.davis.1978.184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneeberger</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grupe</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCluskey</surname>
                    <given-names>RT</given-names>
                  </name>
                </person-group>
                <year>1978</year>
                <article-title>Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children.</article-title>
                <source>Clin Nephrol</source>
                <volume>9</volume>
                <fpage>184</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">657595</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.di_belgiojoso.1977.250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>di Belgiojoso</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarantino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colasanti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bazzi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerra</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durante</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1977</year>
                <article-title>The prognostic value of some clinical and histological parameters in membranoproliferative glomerulonephritis (MPGN): report of 112 cases.</article-title>
                <source>Nephron</source>
                <volume>19</volume>
                <fpage>250</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">917174</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.donadio.1989.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donadio</surname>
                    <given-names>JV</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Offord</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>14</volume>
                <fpage>445</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">2596471</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.dragondurey.2004.787">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dragon-Durey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fremeaux-Bacchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loirat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blouin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niaudet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deschenes</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coppo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herman Fridman</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>15</volume>
                <fpage>787</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">14978182</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.droz.1982.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Droz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noel</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbanel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gr&#x000fc;nfeld</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>1982</year>
                <article-title>Long-term evolution of membranoproliferative glomerulonephritis in adults : spontaneous clinical remission in 13 cases with proven regression of glomerular lesions in 5 cases (author's transl).</article-title>
                <source>Nephrologie.</source>
                <volume>3</volume>
                <fpage>6</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">7088263</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.dsouza.2009.824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D'souza</surname>
                    <given-names>YB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Short</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>IS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonshek</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II.</article-title>
                <source>Kidney Int.</source>
                <volume>75</volume>
                <fpage>824</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19177159</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.duvallyoung.1989.900">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duvall-Young</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Short</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raines</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gokal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawler</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings.</article-title>
                <source>Br J Ophthalmol</source>
                <volume>73</volume>
                <fpage>900</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">2605144</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.eisinger.1972.343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eisinger</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shortland</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moorhead</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>1972</year>
                <article-title>Renal disease in partial lipodystrophy.</article-title>
                <source>Q J Med</source>
                <volume>41</volume>
                <fpage>343</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">4561162</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.farah.2009.416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farah</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fazelat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frei</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Treatment of subretinal neovascular membrane in a patient with membranoproliferative glomerulonephritis type II.</article-title>
                <source>Ophthalmic Surg Lasers Imaging.</source>
                <volume>40</volume>
                <fpage>416</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19634750</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.ferrario.2004.483">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrario</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rastaldi</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Histopathological atlas of renal diseases. Membranoproliferative glomerulonephritis.</article-title>
                <source>J Nephrol</source>
                <volume>17</volume>
                <fpage>483</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15372408</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.fr_meauxbacchi.1994.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fr&#x000e9;meaux-Bacchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brun</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kazatchkine</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <article-title>Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>1994</year>
                <volume>9</volume>
                <issue>7</issue>
                <fpage>811</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">7970124</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.gale.2010.794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gale</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jorge</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Barricarte</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadjisavvas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pusey</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierides</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kyriacou</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Athanasiou</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voskarides</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deltas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000e9;meaux-Bacchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cordoba</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maxwell</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pickering</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.</article-title>
                <source>Lancet.</source>
                <volume>376</volume>
                <fpage>794</fpage>
                <lpage>801</lpage>
                <pub-id pub-id-type="pmid">20800271</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.gonzalo.1986.161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matesanz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teruel</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Incidence of membranoproliferative glomerulonephritis in a Spanish population.</article-title>
                <source>Clinical Nephrology</source>
                <volume>26</volume>
                <fpage>161</fpage>
                <pub-id pub-id-type="pmid">3769232</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.goodship.2006">
              <mixed-citation publication-type="book">Goodship THJ, Fremeaux-Bacchi V, Atkinson JP. Genetic testing in atypical HUS and the role of membrane cofactor protein (MCP; CD46) and factor I. In: Zipfel PF, ed. <italic toggle="yes">Complement and Kidney Disease</italic>. Berlin, Germany: Springer; 2006:111-27</mixed-citation>
            </ref>
            <ref id="mpgn.REF.habib.1975.204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Habib</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loirat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maiz</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1975</year>
                <article-title>Dense deposit disease: a variant of membranoproliferative glomerulonephritis.</article-title>
                <source>Kidney Int</source>
                <volume>7</volume>
                <fpage>204</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">1095806</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.hageman.2005.7227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>LV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hancox</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taiber</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardisty</surname>
                    <given-names>LI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockman</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borchardt</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehrs</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvestri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klaver</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbazetto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yannuzzi</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barile</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merriam</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsh</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergeron</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zernant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merriam</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gold</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allikmets</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>102</volume>
                <fpage>7227</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15870199</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.haines.2005.419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haines</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hauser</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallins</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwan</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noureddine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schnetz-Boutaud</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Postel</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Complement factor H variant increases the risk of age-related macular degeneration.</article-title>
                <source>Science.</source>
                <year>2005</year>
                <volume>308</volume>
                <fpage>419</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">15761120</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.herbert.2007.18960">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herbert</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deakin</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>CQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaum</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pangburn</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uhrin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlow</surname>
                    <given-names>PN</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism.</article-title>
                <source>J Biol Chem</source>
                <volume>282</volume>
                <fpage>18960</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17360715</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.holz.2004.504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holz</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauleikhoff</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>AC</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Pathogenesis of lesions in late age-related macular disease.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>137</volume>
                <fpage>504</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">15013875</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.joiner.1983.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joiner</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawiger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelfand</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>A study of optimal reaction conditions for an assay of the human alternative complement pathway.</article-title>
                <source>Am J Clin Pathol.</source>
                <year>1983</year>
                <volume>79</volume>
                <fpage>65</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">6849295</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.jokiranta.1999.4590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jokiranta</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pangburn</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meri</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.</article-title>
                <source>J Immunol</source>
                <volume>163</volume>
                <fpage>4590</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10510403</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.jungers.1982.899">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jungers</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1982</year>
                <article-title>Is membranoproliferative glomerulonephritis disappearing in France?</article-title>
                <source>Kidney Int</source>
                <volume>21</volume>
                <fpage>899</fpage>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.jungers.1985.264">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jungers</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Rarefaction of membranoproliferative glomerulonephritis (MPGN) in France.</article-title>
                <source>Kidney Int</source>
                <volume>28</volume>
                <fpage>264</fpage>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.kashtan.1990.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kashtan</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gustav Fisker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Dense intramembranous deposit disease: a clinical comparison of histological subtypes.</article-title>
                <source>Clin Nephrol</source>
                <volume>33</volume>
                <fpage>1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">2302866</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.klein.1983.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poucell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arbus</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGraw</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rance</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumal</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Characteristics of a benign subtype of dense deposit disease: comparison with the progressive form of this disease.</article-title>
                <source>Clin Nephrol</source>
                <volume>20</volume>
                <fpage>163</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">6556977</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.kurtz.2002.135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kurtz</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlueter</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Management of membranoproliferative glomerulonephritis type II with plasmapheresis.</article-title>
                <source>J Clin Apher</source>
                <volume>17</volume>
                <fpage>135</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12378549</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.laine.2007.3831">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Laine</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarva</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seitsonen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haapasalo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehtinen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindeman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarvela</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jokiranta</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Immonen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meri</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein.</article-title>
                <source>J Immunol</source>
                <volume>178</volume>
                <fpage>3831</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17339482</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.licht.2006.42">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jozsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loschmann</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perkins</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skerka</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirschfink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGNII).</article-title>
                <source>Kidney Int</source>
                <volume>70</volume>
                <fpage>42</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">16612335</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.lu.2007.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCarthy</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanning</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaney</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porter</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A descriptive study of individuals with membranoproliferative glomerulonephritis.</article-title>
                <source>Nephrol Nurs J.</source>
                <volume>34</volume>
                <fpage>295</fpage>
                <lpage>302</lpage>
                <pub-id pub-id-type="pmid">17644874</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.ludvigsson.2006.1809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ludvigsson</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ekbom</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludvigsson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fored</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Coeliac disease and risk of renal disease-a general population cohort study.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>21</volume>
                <fpage>1809</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">16574681</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.maisch.2004.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maisch</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pezzillo</surname>
                    <given-names>KK</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>HMG-CoA reductase inhibitors for the prevention of nephropathy.</article-title>
                <source>Ann Pharmacother</source>
                <volume>38</volume>
                <fpage>342</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14742776</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.marks.2000.322">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rees</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Spontaneous clinical improvement in dense deposit disease.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>14</volume>
                <fpage>322</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10775078</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mart_nezbarricarte.2010.3702">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Barricarte</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heurich</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valdes-Ca&#x000f1;edo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vazquez-Martul</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torreira</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montes</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortajada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez-Trascasa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Llorca</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez de C&#x000f3;rdoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.</article-title>
                <source>J Clin Invest.</source>
                <year>2010</year>
                <volume>120</volume>
                <fpage>3702</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">20852386</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mathieson.1997.1804">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mathieson</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>DK</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>12</volume>
                <fpage>1804</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9306323</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mcavoy.2004.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McAvoy</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Best</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharkey</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Extensive peripapillary exudation secondary to cat-scratch disease.</article-title>
                <source>Eye</source>
                <volume>18</volume>
                <fpage>331</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15004593</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mcenery.1990.s109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McEnery</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Membranoproliferative glomerulonephritis: the Cincinnati experience cumulative renal survival from 1957 to 1989.</article-title>
                <source>J Pediatr</source>
                <volume>116</volume>
                <fpage>S109</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">2329412</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mcginley.1985.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGinley</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLay</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boulton-Jones</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Plasma exchange in the treatment of mesangiocapillary glomerulonephritis.</article-title>
                <source>Nephron</source>
                <volume>40</volume>
                <fpage>385</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">4022205</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mcrae.2001.6747">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McRae</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Power</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchelhill</surname>
                    <given-names>KI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemp</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>BF</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Human factor H-related protein 5 (FHR-5). A new complement-associated protein.</article-title>
                <source>J Biol Chem</source>
                <volume>276</volume>
                <fpage>6747</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11058592</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.mcrae.2005.6250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McRae</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duthy</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ormsby</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cromer</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKinstry</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parker</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.</article-title>
                <source>J Immunol</source>
                <volume>174</volume>
                <fpage>6250</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15879123</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.misra.2004.18">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Misra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peethambaram</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>83</volume>
                <fpage>18</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">14747765</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.monteferrante.2007.1704">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Monteferrante</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brioschi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caprioli</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pianetti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bettinaglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remuzzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noris</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome.</article-title>
                <source>Mol Immunol</source>
                <volume>44</volume>
                <fpage>1704</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17000000</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.murphy.2002.24">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgiou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McRae</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Factor H-related protein-5: a novel component of human glomerular immune deposits.</article-title>
                <source>Am J Kidney Dis</source>
                <volume>39</volume>
                <fpage>24</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11774097</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.nasr.2009.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nasr</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valeri</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appel</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherwinter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stokes</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markowitz</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Agati</surname>
                    <given-names>VD</given-names>
                  </name>
                </person-group>
                <article-title>Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.</article-title>
                <source>Clin J Am Soc Nephrol.</source>
                <year>2009</year>
                <volume>4</volume>
                <fpage>22</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">18971369</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.nickolas.2003.406">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nickolas</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radhakrishnan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appel</surname>
                    <given-names>GB</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Hyperlipidemia and thrombotic complications in patients with membranous nephropathy.</article-title>
                <source>Semin Nephrol</source>
                <volume>23</volume>
                <fpage>406</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">12923730</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.oberkircher.1988.418">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oberkircher</surname>
                    <given-names>OR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1988</year>
                <article-title>Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapheresis therapy.</article-title>
                <source>Transplant Proc</source>
                <volume>20</volume>
                <fpage>418</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">2964750</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.ohi.1992.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasugi</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).</article-title>
                <source>Clin Exp Immunol</source>
                <volume>89</volume>
                <fpage>479</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">1516262</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.orth.1998.1202">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orth</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritz</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The nephrotic syndrome.</article-title>
                <source>N Engl J Med</source>
                <volume>338</volume>
                <fpage>1202</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">9554862</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.owen.2004.c35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donohoe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bingham</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome).</article-title>
                <source>Nephron Clin Pract</source>
                <volume>96</volume>
                <fpage>c35</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14988595</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.pangburn.1986.723">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pangburn</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller-Eberhard</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.</article-title>
                <source>Biochem J</source>
                <volume>235</volume>
                <fpage>723</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">3638964</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.pickering.2008.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pickering</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>HT</given-names>
                  </name>
                </person-group>
                <article-title>Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.</article-title>
                <source>Clin Exp Immunol.</source>
                <year>2008</year>
                <volume>151</volume>
                <fpage>210</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">18190458</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.rodr_guez_de_c_rdoba.2004.355">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez de C&#x000f3;rdoba</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esparza-Gordillo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goicoechea de Jorge</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez-Trascasa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez-Corral</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The human complement factor H: functional roles, genetic variations and disease associations.</article-title>
                <source>Mol Immunol</source>
                <volume>41</volume>
                <fpage>355</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">15163532</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.ruggenenti.1999.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruggenenti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gherardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoccali</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvadori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scolari</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schena</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remuzzi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.</article-title>
                <source>Lancet</source>
                <volume>354</volume>
                <fpage>359</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">10437863</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.sacks.2003.404">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sacks</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The effect of locally synthesised complement on acute renal allograft rejection.</article-title>
                <source>J Mol Med</source>
                <volume>81</volume>
                <fpage>404</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">12827269</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.sacks.1987.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sacks</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rust</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karagiannis</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jewell</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledingham</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMichael</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Functional and biochemical subtypes of the haplotype HLA-DR3 in patients with celiac disease or idiopathic membranous nephropathy.</article-title>
                <source>Hum Immunol</source>
                <volume>20</volume>
                <fpage>175</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">2960642</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.saunders.2007.222">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abarrategui-Garrido</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fremeaux-Bacchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goicoechea de Jorge</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodship</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez Trascasa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponce Castro</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remuzzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Cordoba</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez-Corral</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skerka</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perkins</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.</article-title>
                <source>Hum Mutat</source>
                <volume>28</volume>
                <fpage>222</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">17089378</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.schwertz.2001.166">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwertz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rother</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anders</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gretz</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirschfink</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up.</article-title>
                <source>Pediatr Allergy Immunol</source>
                <volume>12</volume>
                <fpage>166</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11473682</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.servais.2007.193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Servais</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000e9;meaux-Bacchi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lequintrec</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blouin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gr&#x000fc;nfeld</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesavre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>No&#x000eb;l</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fakhouri</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.</article-title>
                <source>J Med Genet.</source>
                <year>2007</year>
                <volume>44</volume>
                <fpage>193</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17018561</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.sessa.2001.268">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sessa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meroni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daidone</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carnera</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brambilla</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallotti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torri Tarelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calabresi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolleri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertolini</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hypocomplementemic type II membranoproliferative glomerulonephritis in a male patient with familial lecithin-cholesterol acyltransferase deficiency due to two different allelic mutations.</article-title>
                <source>Nephron</source>
                <volume>88</volume>
                <fpage>268</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11423760</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.sethi.2010.977">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sukov</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fervenza</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lager</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>DV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornell</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krishnan</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Dense deposit disease associated with monoclonal gammopathy of undetermined significance.</article-title>
                <source>Am J Kidney Dis.</source>
                <year>2010</year>
                <volume>56</volume>
                <fpage>977</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">20832153</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.simon.1984.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1984</year>
                <article-title>Epidemiological data in population of 250,000 on minimal change nephrotic syndrome. IgA nephrology, idiopathic membranous, and membranoproliferative glomerulonephritis.</article-title>
                <source>Kidney Int</source>
                <volume>26</volume>
                <fpage>512</fpage>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.simon.1987.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramee</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ang</surname>
                    <given-names>KS</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Variations of primary glomerulonephritis incidence in a rural area of 400,000 inhabitants in the last decade.</article-title>
                <source>Nephron</source>
                <volume>45</volume>
                <fpage>171</fpage>
                <pub-id pub-id-type="pmid">3494205</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.simon.1994.1192">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramee</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Autuly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laruelle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charasse</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cam</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ang</surname>
                    <given-names>KS</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Epidemiology of primary glomerular diseases in a French region. Variations according to period and age.</article-title>
                <source>Kidney Int</source>
                <volume>46</volume>
                <fpage>1192</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7861716</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.skerka.2007.3398">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skerka</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinberger</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keilhamer</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000fc;hnel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schl&#x000f6;tzer-Schrehardt</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Defective complement control of FHL-1 and Factor H (Y402H) in age related macular degeneration.</article-title>
                <source>Mol Immunol</source>
                <volume>44</volume>
                <fpage>3398</fpage>
                <lpage>406</lpage>
                <pub-id pub-id-type="pmid">17399790</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.smith.2007.2447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlow</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassavant</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cordoba</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jokiranta</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambris</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanning</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levidiotis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>HU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pickering</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quigg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rops</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salant</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thurman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tully</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tully</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Vlag</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wurzner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipfel</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>New approaches to the treatment of dense deposit disease.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>18</volume>
                <fpage>2447</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">17675665</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.spitzer.1996.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spitzer</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stitzel</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Loss of autoantibody activity by alteration in autoantigen.</article-title>
                <source>Clin Immunol Immunopathol</source>
                <volume>80</volume>
                <fpage>211</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">8764567</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.stone.1999.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lotery</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piguet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guymer</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandenburgh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cousin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swiderski</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvestri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackey</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheffield</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorderet</surname>
                    <given-names>DF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy.</article-title>
                <source>Nat Genet</source>
                <volume>22</volume>
                <fpage>199</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">10369267</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.strobel.2010.1476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strobel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmering</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papp</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prechl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f3;zsi</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Anti-factor B autoantibody in dense deposit disease.</article-title>
                <source>Mol Immunol.</source>
                <year>2010</year>
                <volume>47</volume>
                <fpage>1476</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">20193965</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.study_group_of_the_spanish_society_of_nephrology.1989.370">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Study Group of the Spanish Society of Nephrology</collab>
                </person-group>
                <year>1989</year>
                <article-title>Progressively decreasing incidence of membranoproliferative glomerulonephritis in Spanish adult population.</article-title>
                <source>Nephron</source>
                <volume>52</volume>
                <fpage>370</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">2671766</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.study_group_of_the_spanish_society_of_nephrology.1990.266">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Study Group of the Spanish Society of Nephrology</collab>
                </person-group>
                <year>1990</year>
                <article-title>Decreasing incidence of membranoproliferative GN in Spanish children.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>4</volume>
                <fpage>266</fpage>
                <pub-id pub-id-type="pmid">2400656</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.swainson.1983.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Swainson</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>MK</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Mesangiocapillary glomerulonephritis: a long-term study of 40 cases.</article-title>
                <source>J Pathol</source>
                <volume>141</volume>
                <fpage>449</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">6363655</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.tarshish.1992.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tarshish</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tobin</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edelmann</surname>
                    <given-names>CM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>6</volume>
                <fpage>123</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">1571205</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.walker.2007.605">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrario</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonsib</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Dense deposit disease is not a membranoproliferative glomerulonephritis.</article-title>
                <source>Mod Pathol</source>
                <volume>20</volume>
                <fpage>605</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">17396142</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.west.1986.1077">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>CD</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Childhood membranoproliferative glomerulonephritis: an approach to management.</article-title>
                <source>Kidney Int</source>
                <volume>29</volume>
                <fpage>1077</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">3523004</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.west.2000.786">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAdams</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witte</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Acute non-proliferative glomerulitis: a cause of renal failure unique to children.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>14</volume>
                <fpage>786</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10955928</pub-id>
              </element-citation>
            </ref>
            <ref id="mpgn.REF.zipfel.2006">
              <mixed-citation publication-type="book">Zipfel PF, Smith RJH, Heinen ST. The role of complement in membranoproliferative glomerulonephritis. In: Zipfel PF, ed. <italic toggle="yes">Complement and Kidney Disease.</italic> Berlin, Germany: Springer; 2006:199-221.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="mpgn.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="mpgn.Author_Notes">
          <title>Author Notes</title>
          <p>
            <bold>Contact Information</bold>
          </p>
          <p>Richard JH Smith Division of Nephrology University of Iowa 200 Hawkins Drive Iowa City, IA 52242 Telephone: 319-356-3612 Fax: 319-356-4108 E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="richard-smith@uiowa.edu">richard-smith@uiowa.edu</email></p>
        </sec>
        <sec id="mpgn.Author_History">
          <title>Author History</title>
          <p>Johnny Cruz Corchado (2011-present)Sanjeev Sethi, MD, PhD; Mayo Clinic (2007-2011)Richard JH Smith, MD (2007-present)Peter F Zipfel, PhD habil Prof; Hans Kn&#x000f6;ll Institute (2007-2011)</p>
        </sec>
        <sec id="mpgn.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>19 May 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 January 2008 (rjhs/cd) Revision: clinical testing (sequence analysis) for CFHR5 mutations</p>
            </list-item>
            <list-item>
              <p>20 July 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>17 August 2005 (rjhs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
